From the Toronto Star:
The distributor of a psoriasis drug that is the subject of safety concerns has agreed to suspend sales of it in Canada.
Health Canada recommended that EMD Serono Canada Inc. stop the marketing of Raptiva, the brand name for the drug efalizumab.
Raptiva was authorized in October 2005 for treatment of moderate to severe chronic plaque psoriasis in patients 18 years of age and older.
But use of the drug has been linked to cases of a condition called progressive multifocal leukoencephalopathy or PML, a severe and sometimes fatal neurological disease.
And other serious infections have been seen in people who have taken the drug for three years or more, including Guillain-Barre syndrome, encephalitis, meningitis and sepsis, a bloodstream infection. ...more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment